Effect of Methyl-Sulphonyl-Methane on Osteoarthritis and Cartilage

Phase 1

• Conditions: Osteoarthritis
• Interventions: Drug: MethylSulfonylMethane (MSM); Drug: Placebo

• Registration Number: NCT01836757
• Lead Sponsor: G.Papanikolaou Research Group

Brief Summary

To delineate the effect of MSM on osteoarthritis

Detailed Description

Objective: To delineate the effect of MSM on osteoarthritis of large joints. Design: Randomized, double-blind, placebo-controlled trial including an intervention and a placebo group. One hundred men and women, with hip and/or knee OA to be divided in 2 groups. Intervention is either MSM 3 gr twice a day for 26 weeks (6 gr/day total) for one group and placebo for the other. Outcomes measured are the Western Ontario and McMaster University Osteoarthritis Index visual analogue scale (WOMAC), patient and physician assessments and SF-36 (overall health-related quality of life).

Study Timeline

• Study Start: 2012-09
• Study First Submitted: 2013-03-13
• Status Verified: 2013-04
• Study First Submitted QC: 2013-04-17
• Last Update Submitted: 2013-04-17
• Study First Posted: 2013-04-22
• Last Update Posted: 2013-04-22
• Primary Completion: 2013-09
• Study Completion: 2013-10

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Knee and hip OA
• men and women >45 years of age

Exclusion Criteria

• any other type of arthritis
• chronic pain syndrome
• arthroscopic surgery in the past 8 months
• intra-articular corticosteroidsin the past 8 months
• hyaluronic acid injections in the past 8 months
• narcotic pain killers use
• renal or hepatic disease
• body mass index (BMI) >45 kg/m2
• cancer

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
MSM group	MethylSulfonylMethane (MSM)	Intervention is MSM 3 gr twice a day for 26 weeks (6 gr/day total)
Placebo Group	Placebo	Placebo 3 gr twice a day for 26 weeks (6 gr/day total)

Primary Outcome Measures

Name	Time	Method
Number of participants with improved Mobility	26 weeks	Randomized, double-blind, placebo-controlled trial including an intervention and a placebo group. One hundred men and women, with hip and/or knee OA were divided in 2 groups. Intervention was either MSM 3 gr twice a day for 26 weeks (6 gr/day total) for one group and placebo for the other. Outcomes measured were the Western Ontario and McMaster University Osteoarthritis Index visual analogue scale (WOMAC)

Secondary Outcome Measures

Name	Time	Method
Pain Scores on the Visual Analog Scale	26 weeks	On the same two groups (MSM and Placebo)we measured the improvement of quality of life through pain relief as measured by use of SF-36 (overall health-related quality of life)

Trial Locations

Locations (1)

G. Papanikolaou Hospital; 🇬🇷 Thessaloniki, Greece